Novo Nordisk cut off Hims & Hers Health from selling lower-priced Wegovy on Monday morning, but its explanation for the ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

Hims & Hers ( HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk ( NVO) announced it was ending a ...

While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...

Novo Nordisk (NVO) and Hims and Hers Health (HIMS) shares are sinking on an ended partnership, with the former also ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Hims & Hers Health Inc.'s stock fell sharply on Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the ...

Novo Nordisk ends partnership with Hims & Hers over safety and marketing concerns tied to compounded Wegovy, as rivalry with ...

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

Diabetes treatment with semaglutide was associated with significantly reduced risk for stroke compared with empagliflozin, ...

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, ...